Anifrolumab, Matching placebo solution for injection in aPFS; 0.8 mL fill volume
D346BC00001
Phase 3 small_molecule active
Quick answer
Anifrolumab, Matching placebo solution for injection in aPFS; 0.8 mL fill volume for Cutaneous Lupus Erythematosus is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Cutaneous Lupus Erythematosus
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active